pharma industry shuns trump push for radical shift at fda
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle

Pharma industry shuns Trump push for radical shift at FDA

Themuslimchronicle, themuslimchronicle

Themuslimchronicle, themuslimchroniclePharma industry shuns Trump push for radical shift at FDA

U.S. Food and Drug Administration
New York - Arab Today

US President Donald Trump’s vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration (FDA) would make it harder to secure insurance coverage for pricey new medicines.
The prospect of big change at the regulatory agency comes as drugmakers are under fire for high prices, including Marathon Pharmaceuticals LLC., which said Monday it was “pausing” the launch of its Duchenne muscular dystrophy drug after US lawmakers questioned its $89,000 a year price.
Industry trade group Biotechnology Innovation Organization (BIO) told Reuters that during high-level discussions with Trump advisers, lobbyists urged the administration not to name a new commissioner of the FDA who would act rashly to speed up the agency’s approval of new medicines.
That sentiment was echoed by executives at more than a dozen pharmaceutical and biotechnology firms, who told Reuters that the FDA is already adopting new drug development models and warned that a looser review process would put patients at risk.
“People often argue that the FDA is too restrictive,” said Roger Perlmutter, head of research and development at Merck & Co. Inc. “We have the sense that the balance is pretty right ... you have to have a well-characterized risk/benefit profile.”
That stance underscores the unique position the drug industry finds itself in when it comes to regulating its products. While most sectors welcome less oversight, drugmakers say a robust review process is critical in convincing physicians and insurers that a pricey new medicine has value.
Otherwise, the time and money it takes to get a new drug to market — estimates run as high as $2.6 billion — would be lost if insurers are not willing to pay for the product.
“It is great that the administration is seeking deregulation ... to make sure the private sector can be more competitive,” said John Maraganore, chief executive officer at Alnylam Pharmaceuticals Inc. and co-chair of BIO’s regulatory committee. “But payers are looking for evidence of value.”
He said the FDA should speed the approval of lower cost generic versions of drugs that have lost patent protection, but warned that allowing novel products to be launched without extensive testing could be dangerous.
“Any change at the FDA that allows drugs to be tried out on patients without clinical evidence is a damaging approach,” said Jeremy Levin, chief executive officer at Ovid Therapeutics Inc., which is developing drugs for rare diseases.
Health insurers are pushing back against high-priced drugs. Sales of expensive new cholesterol drugs from Amgen Inc. and Regeneron Pharmaceuticals Inc. have stalled as insurers limit coverage until they see results of trials designed to prove that the drugs significantly lower the risk of heart attack and other cardiovascular crises.
To be sure, some pharmaceutical executives have been vocal about the need for deregulation. Reducing regulation “will help with drug prices, because it will induce more competition,” Pfizer Inc. CEO Ian Read said on a recent conference call.
After top executives at Merck, Johnson & Johnson and others met at the White House last month with Trump, who pledged to “streamline” the FDA, industry trade group Pharmaceutical Research and Manufacturers of America said the meeting found common ground such as tax reform, and removal of outdated regulations. The trade group declined to comment on changes at the FDA.
The prospect of a shake-up at the FDA is being welcomed by a new class of investor with ambitions to disrupt the current drug development model, in which larger pharmaceutical players often buy or license early-stage medicines, and reap the bigger rewards if they succeed.
A recent survey of drug company executives conducted by Mizuho Securities found that 72 percent said Gottlieb should be Trump’s pick to head the FDA.
“There is no groundswell of movement for change,” said attorney Jim Shehan, head of Lowenstein Sandler’s FDA regulatory practice. “The industry likes certainty.”

Source: Arab News

themuslimchronicle
themuslimchronicle

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

pharma industry shuns trump push for radical shift at fda pharma industry shuns trump push for radical shift at fda

 



Themuslimchronicle, themuslimchronicle

GMT 08:32 2011 Monday ,25 July

Sabri accuses Yusri in Souad Hosni’s murder

GMT 12:07 2014 Monday ,03 February

Home design ideas

GMT 11:20 2017 Thursday ,02 March

Mexico central bank cuts growth outlook over Trump

GMT 08:31 2017 Tuesday ,28 November

Bangladesh upholds death sentence for 139 soldiers

GMT 14:33 2017 Thursday ,20 April

US defense secretary vows support for Egypt's Sisi

GMT 16:12 2017 Wednesday ,20 December

Myanmar bars UN rights investigator just before visit

GMT 08:21 2017 Wednesday ,30 August

United Technologies near deal to buy Rockwell Collins

GMT 18:27 2017 Friday ,21 April

ARCO condemns targeting of ERC convoy in Somalia

GMT 07:23 2017 Tuesday ,21 November

perched in Jerusalem's hills may soon vanish

GMT 19:33 2017 Tuesday ,10 October

US scientists engineer corn to boost protein

GMT 08:43 2017 Monday ,04 December

Brexit deal 'difficult but doable': diplomats

GMT 11:24 2017 Friday ,03 March

Lego honors 'Women of NASA'

GMT 11:35 2017 Tuesday ,05 December

Bahrain's top Shiite cleric hospitalised

GMT 21:39 2017 Saturday ,30 September

Abdel Karim praises Egypt’s role

GMT 10:11 2017 Tuesday ,12 December

Latest Grateful Dead resurrection -- a duo

GMT 15:43 2017 Monday ,04 December

Yemen's Huthi rebels claim ex-president Saleh killed

GMT 15:59 2017 Thursday ,30 November

Bahrain Bourse daily trading performance
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
 
 Themuslimchronicle Facebook,themuslimchronicle facebook  Themuslimchronicle Twitter,themuslimchronicle twitter Themuslimchronicle Rss,themuslimchronicle rss  Themuslimchronicle Youtube,themuslimchronicle youtube  Themuslimchronicle Youtube,themuslimchronicle youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

muslimchronicle muslimchronicle muslimchronicle muslimchronicle
themuslimchronicle themuslimchronicle themuslimchronicle
themuslimchronicle
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
themuslimchronicle, themuslimchronicle, themuslimchronicle